Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Kind of surprising on both.
Celgene says Barr withdrew generic Thalomid filing
http://finance.yahoo.com/news/Celgene-says-Barr-withdrew-apf-2797620331.html?x=0&.v=1
On Thursday May 27, 2010, 8:10 am EDT
SUMMIT, N.J. (AP) -- Celgene Corp. said Thursday that a competitor withdrew its application for a generic version of Celgene's cancer drug Thalomid.
Celgene said Barr Laboratories withdrew the application, which had been filed in 2006 with the Food and Drug Administration.
As a result, Celgene said it had dropped a 2007 patent infringement lawsuit against Barr.
Celgene markets Thalomid, or thalidomide, as a treatment for multiple myeloma, which is a cancer that affects bone marrow.
The company filed suit against Barr Pharmaceuticals in January 2007, saying Barr's proposed generic violated patents held by Celgene. Barr was acquired in late 2008 by Teva Pharmaceutical Industries Ltd., the world's largest maker of generic drugs.
way beyond the scope of even this discussion
Too easy for a geneticist :)
I assume Monsanto's corn seeds are hybrids. Not much use in replanting hybrids as what regrows will not have the original seed's genotype and its desirable genetic traits.
[OT] One more thing on the “therapeutic treatment” aj recommended - seeing the expression on the face of a guy who doesn't like the taste might be a libido killer. So, if you don't like caviar, don't eat it...
MDT Resolute stent had a fairly good showing VS Xience
Gilenia review period extended by three months, to September.
http://www.msrc.co.uk/index.cfm/fuseaction/show/pageid/1309
Yes, good timing to start picking.
Now we have the rising tension on the Korean region on top of the European debt crisis and Asian stock markets along with Europeans are falling. Btw, TEVA is one of the few green stocks at TASE this morning.
Gal Bernstein was right on Rituxan: Teva is developing a biosimilar version:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01123070
Scientific Meeting Calendar
NOTE: ANYONE MAY UPDATE THIS FILE
Edits: Added EAPCI, ICAD.
MAY 2010
International Society on Thrombosis & Haemostasis - ISTH
Cairo, Egypt
May 22-25, 2010
http://www.isth.org/
American Society for Microbiology - ASM
San Diego, CA
May 23-27, 2010
http://www.asm.org/
European Association of Percutaneous Cardiovascular Interventions - EAPCI
Paris, France
May 25-28, 2010
http://www.europcr.com/
American Urological Association - AUA
San Francisco, CA
May 29 - June 3, 2010
http://www.auanet.org/content/homepage/homepage.cfm
JUNE 2010
American Society of Clinical Oncology - ASCO
Chicago, IL
June 4-8, 2010
http://chicago2010.asco.org/Home.aspx
World Ophthalmology Congress - WOC
Berlin, Germany
June 5-9, 2010
http://www.woc2010.org/
European Hematology Association - EHA
Barcelona, Spain
June 10-13, 2010
http://www.ehaweb.org/
European Society of Human Genetics - ESHG
Gothenburg, Sweden
June 12-15, 2010
https://www.eshg.org/
Psychopharmacologic clinical research - NCDEU
Boca Raton, FL
June 14-17, 2010
http://www.ncdeumeeting.org/NCDEU%202010.htm
European League Against Rheumatism - EULAR
Rome, Italy
June 16-19, 2010
http://www.eular.org/
Endocrine Society - ENDO
San Diego, CA
June 19-22, 2010
http://www.endo-society.org/
European Neurological Society - ENS
Berlin, Germany
June 19-23, 2010
http://www.ensinfo.org/
American Diabetes Association - ADA
Orlando, FL
June 25-29, 2010
http://www.diabetes.org/
European Association for Cancer Research - EACR
Oslo, Norway
June 26-29, 2010
http://www.eacr.org/
JULY 2010
International Conference On Alzheimer's Disease - ICAD
Honolulu, Hawaii
July 10-15, 2010
http://www.alz.org/icad/2010_icad.asp
OCTOBER 2010
American Association for the Study of Liver Diseases - AASLD
Boston, Massachusetts
October 29 - November 2, 2010
http://www.aasld.org/
NOVEMBER 2010
American Society of Human Genetics - ASHG
Washington, DC
November 2-6, 2010
http://www.ashg.org/
----
Procedure for Updating Calendar
When adding or modifying entries, please follow these steps:
1. Copy the complete text from the old calendar.
2. Make your additions or modifications, inserting any new items in chronological order.
3. Near the top of the message, give a very brief description of your changes (e.g. “Edits: Added entry for AASLD”).
4. Post the updated calendar in a new message as a reply to the message with the old calendar.
So far, NVS is the only Big Pharma that hasn’t lowered sales and EPS guidance to account for ObamaCare. Why hasn’t it? Simple arithmetic: 60% of NVS’ sales come from the pharma division and only one-third half of that comes from the US
This one calls for an Einstein quote: "Only two things are infinite, the universe and human stupidity, and I'm not sure about the former."
But JAK2, BRAF, Btk, ALK for targets seem exciting to me to name a few.
Exactly so, skinny
Hag Sameh!
Good surprise to Forest/Nycomed. Seems that Daxas could be in the market in less than a year.
Teva's CFO Eyal Desheh said at the Oppenheimer annual conference in Tel Aviv, that the healthcare reform will reduce Teva's revenue by $80-100M a year.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000560272&fid=942
Glass is another contaminant that is often observed during quality control screening. Glass particles can be generated by fracture of the vial neck or opening, from external sources such as other vials, glassware and lighting, and from delamination of the inner vial surface. Because of their density, glass particles sink rapidly to the bottom of the vial when the liquid is agitated. Glass delamination flakes are extremely thin and may be missed during visual examination. If a larger number are present, a “twinkling” effect in the solution is observed. The “twinkling” is best observed using a fiber optic light source. Delamination flakes do not sink to the bottom of the vial. Glass delamination usually occurs when a highly acidic, highly basic or sodium chloride solution is stored in the wrong type of container.
Of course the vials were OK when they left the plant, those tiny flake-like glass particles are clever slippery things
Isn't Gammagard being manufactured in the same place as Hylenex?
Talampanel, a non-competitive AMPA antagonist which Teva got from Ivax, joined the graveyard of failed ALS drugs:
http://www.tevapharm.com/pr/2010/pr_932.asp
Ikaria Inc filed with U.S. regulators on Thursday to raise up to $200 million in an initial public offering of common stock. Btw, BL-1040 is IK-5001 in Ikaria's pipeline:
http://www.ikaria.com/investors/pipeline.html
Gandy wrote the editorial in Lancet that accompanied the bapineuzumab pib-pet paper. In that editorial, he took much of his editorial space to talk about how dimebon was very promising and going to be a gamechanger in AD.
Notably, also on the horizon in Alzheimer’s treatment is latrepirdine, a retired Russian antihistamine with surprising apparent benefit in both Alzheimer’s disease and Huntington’s disease. The mechanisms of action of latrepirdine are poorly understood but they are rapidly becoming a focus of great interest. New information suggests that the mechanisms might involve the protein aggregation phenomena that are involved in both diseases. Latrepirdine modulates amyloid-beta metabolism in vivo in amyloid precursor protein transgenic mice and accelerates clearance of protein deposits from synuclein transgenic mice. Although it is premature to say that we have effective, disease-modifying drugs available, these emerging data concerning both bapineuzumab and latrepirdine move us closer to the goal of understanding, treating, and, eventually, preventing major neurodegenerative diseases such as Alzheimer’s disease
Gandy obviously meant in humans. However, in order to be balanced he should have added that we don't know the precise role of non-plaque A-beta peptides such as soluble oligomers in humans either. The paradigm shift away from full-fledged fibrils to oligomeric ("soluble") assemblies being the primary neurotoxic form is backed by several lines of evidence (papers are since 2001, I think) but all in cells and mice.
Gandy said the Lancet Neurology study may simply mean that patients need to be treated longer to benefit from bapineuzumab.
J. Woodcock, FDA/CDER to Teva Neurosciene, Inc. - Petition Denial
You can download the .pdf (12 pages) from this link:
http://www.regulations.gov/search/Regs/home.html#documentDetail?R=0900006480aec10a
FRX
There's a very good chance the FDA will ask for another clinical trial before approving Daxas. We'll know next week.
Oppenheimer also downgraded TEVA to Perform and removed its $65 price target.
Perhaps MRK is trying to back up its argument for the arbitration with JNJ regarding rights to Remicade. MRK is claiming that the merger was structured in reverse so Schering purchased Merck and this is the "New Merck" and therefore does not violate the contract between Schering and JNJ,.
The rapid onset of resistance is a feature of HCV protease inhibitors in general, not just Telaprevir. These drugs clearly can't be used as monotherapy.
Salix drug effective for bowel symptoms
http://www.reuters.com/article/idCNN0323553620100503?rpc=44
* Xifaxan relieves non-constipation IBS symptoms
* Shares rise 7 percent
LOS ANGELES, May 3 (Reuters) - A pivotal trial of Salix Pharmaceuticals Ltd's <SLXP.O> Xifaxan has shown the antibiotic relieves symptoms, other than constipation, of irritable bowel syndrome, the company said on Monday.
Results from the 1,260-patient trial of a 550 mg dose of the drug were presented at the annual Digestive Disease Week meeting in New Orleans.
The trial found that 14 days of treatment with Xifaxan, also known as rifaximin, resulted in significant improvement of symptoms, including bloating, stool consistency and abdominal pain and discomfort, according to Salix.
It also said the safety profiles were similar between Xifaxan and placebo.
"It is notable that two weeks of rifaximin treatment resulted in a sustained response over three months; while, with other treatments, symptom relief dissipates rapidly after therapy is withdrawn," Bill Forbes, head of the company's research and development, said in a statement.
He said Salix is working to submit an application to the U.S. Food and Drug Administration by the end of June.
Xifaxan is already approved by the FDA for so-called travelers' diarrhea caused by certain strains of E. coli bacteria and was approved in March for reducing the risk of recurrent hepatic encephalopathy, a disorder caused by chronic liver failure that can cause confusion, memory problems or coma.
Sales of the drug totaled $118 million last year.
Cephalon's cancer drug Treanda (Bendamustine) 1Q10 sales rose 62% to $81.3M.
King's Thrombin-JMI sales slid 21% to $37M during 1Q10.
http://money.cnn.com/news/newsfeeds/articles/reuters/MTFH57081_2010-05-05_12-20-33_N05170869.htm
KG/ACUR - no more niacin:
King Pharmaceuticals and Acura Pharmaceuticals Announce Plans to Submit an NDA for Acurox(R) Tablets Without Niacin
http://finance.yahoo.com/news/King-Pharmaceuticals-and-iw-4202527499.html?x=0&.v=1
Submission Targeted for Early 2011
BRISTOL, TN and PALATINE, IL--(Marketwire - 05/03/10) - King Pharmaceuticals, Inc. (NYSE:KG - News) and Acura Pharmaceuticals, Inc. (NASDAQ:ACUR - News) today announced that the Companies plan to develop and submit a New Drug Application (NDA) for Acurox® (oxycodone HC1) Tablets (without niacin) intended to relieve moderate to severe pain and introduce limits and impediments to potential abuse via nasal snorting of crushed tablets and intravenous injection of dissolved tablets. At an April 22, 2010 joint Advisory Committee meeting, the U.S. Food and Drug Administration (FDA) questioned the effectiveness of niacin included in the current Acurox® formulation but cited no concerns with the snorting and intravenous abuse limiting features of the product. The Companies expect to submit an NDA for Acurox® Tablets (without niacin) in early 2011.
The Companies also plan to develop and submit NDAs for two additional immediate release opioid analgesic products utilizing Acura's proprietary Aversion® Technology; Vycavert® (hydrocodone bitartrate/acetaminophen) Tablets and Acuracet® (oxycodone HCl/acetaminophen) Tablets. Like Acurox®, these additional product candidates are patent protected compositions comprising a mixture of active and inactive ingredients intended to relieve pain and introduce limits and impediments to nasal and intravenous abuse.
MYGN - ouch
Myriad Genetics posts weak Q3, sees FY10 below Street
http://www.reuters.com/article/idCNSGE6430KE20100504?rpc=44
May 4 (Reuters) - Myriad Genetics Inc (MYGN.O) posted lower-than-expected quarterly results hurt by restrained sales and forecast full-year results below analysts' estimates, driving down its shares as much as 26 percent in after-market trade.
Chief Executive Peter Meldrum said: "While revenues for the quarter followed seasonal growth patterns, macroeconomic conditions continued to impact the frequency of physician visits, which remain well below historic levels."
For the third quarter ended March 31, net income was $33.3 million, or 33 cents a share, compared with $25.3 million, or 25 cents a share a year ago.
Molecular diagnostic revenue, which accounts for all its revenue, rose 5 percent to $90.8 million.
Analysts on average were expecting a profit of 39 cents a share, before items, on revenue of $97.8 million, according to Thomson Reuters I/B/E/S.
For full-year 2010, the company expects to earn between $1.30 and $1.35 a share, on revenue between $360 million and $365 million.
Analysts on average expect earnings of $1.50 per share, excluding items, on revenue of $381.5 million.
Shares of the company fell 25 percent to $17.99 in after market trade. They closed at $24.08 Tuesday on Nasdaq.
New Cancer Vaccine the Next Dendreon?
http://www.thestreet.com/story/10743730/1/the-next-dendreon-not-likely.html
Adam Feuerstein 05/03/10 - 01:03 PM EDT
BOSTON (TheStreet) -- Think all cancer vaccines are, or will be, successful? Think again.
Before there was Dendreon(DNDN) and its just-approved prostate cancer vaccine Provenge, there was Cell Genesys and Favrille, CancerVax and Genitope(GTOP.PK). All tried to develop cancer vaccines, all failed.
Dendreon's stock price is surging; those other four cancer vaccine companies -- not so much. Favrille and CancerVax are no longer with us. Genitope exists in pink sheet purgatory. Only Cell Genesys managed to survive, sort of, by selling itself to BioSante Pharmaceuticals(BPAX), a small drug company better known for trying to develop a female Viagra.
Dendreon is a great success story and proves that patience and perseverance can pay off in the fledgling field of cancer immunotherapy. But let's not also forget that Dendreon is a lonely winner surrounded by a crowd of cancer vaccine losers.
In the next weeks and months, investors are going to be enticed by drug companies crawling out of the woodwork with claims that they're working on the next Provenge. That's an easy thing to say, much tougher to actually accomplish.
Biotech investors are busy looking for the "next Dendreon." Nothing wrong with searching for new cancer vaccines, as long as investors remember that, once upon a time, some other investors bought Favrille and Genitope, CancerVax and Cell Genesys confident that they already owned the next Dendreon.
It didn't quite work out that way, unfortunately.
On Monday, BioSante said it was resurrecting the GVAX prostate cancer vaccine program that caused Cell Genesys to blow up in 2008.
Too new to the cancer vaccine game to remember what happened to Cell Genesys and GVAX? Here's a quick history lesson. Independent data safety monitors in August 2008 forced Cell Genesys to shutter one phase III clinical trial of GVAX because prostate cancer patients treated with GVAX and chemotherapy were dying at a faster rate than those patients treated with chemotherapy alone.
Cell Genesys stopped the second and final GVAX phase III study in October 2008 due to futility, meaning GVAX was deemed too ineffective to benefit prostate cancer patients.
GVAX was doomed from the start because data from phase II studies of the cancer vaccine were fairly lousy. Of course, that didn't stop Cell Genesys from signing a partnership with the Japanese drug maker Takeda, or for investors who thought they knew better to lose all their money when Cell Genesys' stock price sank to mere pennies.
Hope apparently springs eternal in the Provenge post-approval era.
"Now that the FDA has approved the first-ever therapeutic cancer vaccine, Provenge, for the treatment of prostate cancer, we have renewed confidence that our GVAX Prostate can be a valuable addition to prostate cancer patient care," said BioSante CEO Stephen Simes in Monday's press release.
Nice touch, linking Provenge and GVAX.
Antigenics(AGEN) and its cancer vaccine Oncophage is a two-time loser, having failed phase III studies in melanoma and kidney cancer.
Antigenics did manage to secure Oncophage's approval in Russia in 2008, although it took until this year for a single Russian patient to actually pay for treatment with the drug. European regulators rejected Oncophage in 2009 and the clinical data from phase III studies and post-hoc survival registries is of such low quality that Antigenics can't even approach the U.S. Food and Drug Administration about seeking approval here.
Antigenics continues to pursue Oncophage's development, with data from a phase II brain tumor study expected later this year.
Overall, a dozen experimental cancer vaccine programs have failed phase III studies, according to a list compiled by MD Becker Partners as part of an in-depth cancer vaccines report published recently by the biotech consulting firm.
MD Becker Partners' principal Michael Becker, in his report, identifies two main reasons for why cancer vaccines have a historically high failure rate. First, companies rushed cancer vaccines into the human testing without understanding how they worked on a molecular level. As a result, many early cancer vaccines lacked potency and were unable to provoke an immune response strong enough to fight off tumor cells.
Second, drug companies tried to develop cancer vaccines on the cheap. Instead of spending money on robust mid-stage studies to winnow out potential winners from the losers, companies moved quickly into large, high-risk phase III studies, he says.
Cel-Sci(CVM) is expected to start a phase III study of its cancer vaccine Multikine in head and neck cancer patients this summer, despite limited and relatively weak data from phase II studies.
Two more cancer vaccine stocks investors should regard with caution: Northwest Biotherapeutics(NWOB.OB) and its brain cancer vaccine DCVax; and BioVest International(BVTI.PK), developer of BiovaxID for non-Hodgkin's lymphoma.
[BioVest and its companion company Accentia Pharmaceuticals presented phase III data on BiovaxID at the plenary session of last year's American Society of Clinical Oncology annual meeting. Yet the companies have yet to seek regulatory approval for the drug.]
Think you have the next Dendreon of the cancer vaccine world? The odds say you don't.
Latisse is a prescription treatment and AGN has marketed it aggressively to docs (both dermatologists and ophthalmologists) and DTC but apparently there are some online sales which bypass a doctor’s prescription or visit:
Long Lashes Without Prescription, but With Risks
http://www.nytimes.com/2010/05/02/health/02latisse.html?scp=3&sq=drug&st=cse
By CATHERINE SAINT LOUIS, May 1, 2010
If women want to grow longer, fuller, darker eyelashes, Brooke Shields suggests on a ubiquitous television advertisement that they ask their doctors if Latisse is right for them.
But in the case of Latisse, which has sold more than a million bottles to date and gained something of a cult following, it turns out to be easy to bypass a doctor’s prescription or visit.
Some salon workers dispense it to clients who go in for facials. Web sites in the United States and abroad sell it outright with few questions asked. Even doctors are getting into the act: for example, Dr. Anshul V. Gambhir, a former primary care doctor, runs www.latisse.bz, which boasts that it is the “largest Latisse retailer.” All it takes to get Latisse mailed out — without ever seeing him — is filling out a medical history, which he reviews, and typing in a valid credit card number.
“We are doing a ton of business,” said Dr. Gambhir, who also offers Latisse at his three offices in Pennsylvania.
Most people use Latisse, a topical solution, with few, if any, complaints. But the drug can cause redness, itchiness and irritation, which go away if use is discontinued. Less common is eyelid discoloration, which Allergan, the manufacturer, says “may be reversible.” A rare side effect that has captured the most attention is the chance that one’s hazel or blue eyes could turn brown — forever.
But if people use Latisse without seeing a doctor, the side effects may come as a big surprise. Cynthia O’Connor, an interior designer from Minneapolis, got Latisse from the woman who does her facials, who works out of the office of a plastic surgeon who is listed as a Latisse provider on Allergan’s Web site. The woman did not ask her medical history or mention a single risk, Ms. O’Connor said, and she never met the doctor.
When “very dark purply” discoloration showed up on her eyelids, Ms. O’Connor was perplexed, but took it in stride because her new plum “eye shadow” garnered compliments. Then, the purple hue appeared under her eyes, where she had never applied Latisse.
“It looked like I hadn’t slept in a month,” said Ms. O’Connor, 58. “It was horrible.”
Five months ago, she stopped using Latisse, but some discoloration is still visible.
Allergan has a policy against selling Latisse online and says it will cut off supplies to doctors who do so. “Allergan strongly believes consumers should seek consultation from a qualified doctor to determine if they are an appropriate candidate for treatment,” said Heather Katt, an Allergan spokeswoman.
Consumers have long been able to obtain some prescription drugs illicitly without seeing a doctor — think of the flurry of Web advertisements for generic Viagra — but with Latisse, it is striking how routinely no-prescription sales of the real product take place in plain sight. The high cost of the drug, $89 to $150 for a month’s supply (depending on the markup), seems to offer a powerful incentive to all kinds of would-be salespeople.
Since Dr. Gambhir started prescribing the lash-enhancing drug last summer, he said, he has put an estimated “10,000 bottles out there,” and “a good bit are online transactions.” (Though many states prohibit doctors from selling drugs online without seeing the customers, Pennsylvania does not.)
Asked about Allergan’s policy against online sales of Latisse, Dr. Gambhir said, “Allergan is aware that Latisse is being sold online by myself.”
Other Latisse providers said in interviews that their Allergan representatives knew about online sales. Dr. Peter J. Sacchetti of York, Me., said that his Allergan representative had provided before-and-after pictures for his Web site, but that he had not started selling Latisse online because of concerns raised by his insurance company. (His Web site does say that a consultation is required before buying Latisse.)
Ms. Katt said Allergan had shut down two health care providers who were selling Latisse online and was investigating 12 others. But she said that most online sales of Latisse were illegal ones over which Allergan had no control, either because the product was being smuggled into the country or because it was really a generic knockoff not approved by the Food and Drug Administration.
Latisse is the same formula as Lumigan, Allergan’s eyedrops for glaucoma, which reduces eye pressure but also happens to grow lashes. Both are also known as bimatoprost ophthalmic solution. In early 2009, Allergan introduced the drug as a lash enhancer. According to Ms. Katt, Allergan sold $73.7 million worth of Latisse last year, expects to sell $140 million of it this year and estimates that net sales could ultimately exceed $500 million a year.
Some doctors said it was common knowledge that Latisse was easily available without a prescription.
“They say in the patient packet insert that it is doctor-prescribed, and that’s not true,” said Dr. Seth L. Matarasso, a dermatologist in San Francisco. “Patients in my area say they found it in their health club. It is dispensed by a variety of people. Controls are not that strict.”
Dr. Matarasso injects his fair share of Botox but said his sales of Latisse were “not astronomical,” largely because it is so easy to obtain. He does not sell Latisse online and does require an in-person consultation.
The risks for consumers vary. The Latisse they buy online could be adulterated or fake. But even when the Latisse is the bona fide Allergan product, bypassing a doctor means a patient is not necessarily taught proper application or made aware of the potential problems.
“When the F.D.A. approved this product for marketing, they made a determination that the side effects or misuse or inappropriate use could cause harm, and that’s why they restricted it to a prescription drug,” said Carmen A. Catizone, the executive director of the National Association of Boards of Pharmacy, which represents state agencies that regulate pharmacies and pharmacists. “If it was completely safe to use without doctor supervision, they would have deemed it over-the-counter.”
Excluding ophthalmologists, most doctors do not do eye exams before dispensing Latisse, but they do explain how to apply it. Latisse must be dabbed on the upper lash line only, since it can grow unintended hair — on the cheek, for example. People are not supposed to place it on the lower lash line or eyebrows (though some do), and they are meant to use the one-use applicators that come with Latisse to avoid infection and to give the right dose.
Without a doctor’s guidance, “it’s a cumulative risk,” said Dr. Andrew G. Iwach, executive director of the Glaucoma Center of San Francisco. “Let’s say you use the product once inappropriately, or outside the approved guidelines, you might get away with it, but this drug is being applied repeatedly over weeks, months and potentially years. The consequences, or risk of consequences, add up over time.”
Most people who use Latisse or Lumigan do well, Dr. Iwach said. Still, he said issues did arise, like ingrown lashes, when lashes get so long they scratch the cornea. Latisse can also reactivate dormant eye inflammation. “When it’s something as personal, something so critical as vision, you don’t want to cut corners,” Dr. Iwach said.
Even so, some people’s enthusiasm for Latisse is hard to overstate.
Last week, Brad Denherder, a 21-year-old hairdresser in Seattle, got Latisse from a client as a gift. He believes that his lashes lack fullness and said he could not wait to use Latisse: “I want them to be so long that they create wind tunnels.”
Victoria Parker, 39, is thrilled by her “teenager lashes” and relieved that after four months of Latisse use, her blue eyes have not gone brown. “I’m in for life,” said Ms. Parker, a licensed child care provider in Tacoma, Wash. “I can’t go back to having no eyelashes.”
Ms. Parker buys her Latisse on a Web site run by two registered nurses in Pennsylvania, who send their customers’ medical histories to Dr. Lori Alfonse, a breast surgeon in East Norriton, Pa., for review before packing up Latisse.
Dr. Alfonse, whose practice is listed as a Latisse provider at Allergan’s site, has no qualms. Latisse, she said in an interview, is “not a controlled substance.”
I'd never heard of Seaside Therapeutics until now.